Преимущества и недостатки использования прокальцитонина в клинике

Автор: Багирова Н.С., Петухова И.Н., Григорьевская З.В., Терещенко И.В., Дмитриева Н.В.

Журнал: Злокачественные опухоли @malignanttumors

Статья в выпуске: 3S1 т.9, 2019 года.

Бесплатный доступ

В качестве дополнения к другим клиническим и лабораторным параметрам прокальцитонин (ПКТ) предоставляет диагностическую, прогностическую и терагностическую информацию, и прежде всего при сепсисе и инфекциях дыхательных путей. ПКТ информативен при проведении дифференциальной диагностики между лихорадкой инфекционной и неинфекционной природы, бактериальной и вирусной этиологии. При бактериальном сепсисе уровень ПКТ значительно возрастает (обычно более 2 нг / мл), снижаясь при адекватной антибактериальной терапии (АБТ). При вирусных инфекциях значения ПКТ остаются в пределах нормы или незначительно повышаются. У здоровых людей ПКТ не более 0,01 нг/ мл, при вирусных инфекциях - редко более 1 нг/ мл. ПКТ как прогностический маркер дает возможность корректировать проведение дальнейших диагностических исследований, использовать иные терапевтические стратегии, прежде всего в отношении антимикробной терапии. Введение ПКТ в алгоритм лечения требует серии исследований уровня ПКТ, но не однократного его определения...

Еще

Прокальцитонин, онкологические пациенты, сепсис, фебрильная нейтропения

Короткий адрес: https://sciup.org/140249193

IDR: 140249193 | DOI: 10.18027/2224-5057-2019-9-3s1-32-42

Список литературы Преимущества и недостатки использования прокальцитонина в клинике

Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit.Care 2010;14: R15. 10.1186 / cc8872 DOI: 10.1186/cc8872
de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, openlabel trial. Lancet Infect Dis 2016;16:819e27. http://dx.doi.org / 10.1016
Bonita Durnaś, Marzena Wątek, Tomasz Wollny, Katarzyna Niemirowicz, Michał Marzec, Robert Bucki, Stanisław Góźdź. Utility of blood procalcitonin concentration in the management of cancer patients with infections. OncoTargets and Therapy 2016;9:469- 475. http://dx.doi.org / 10.2147 / OTT.S95 600 \\ DOI: 10.2147/OTT.S95600
Maruna P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin. Physiol Res. 2000;49 (Suppl 1):S57 - S61. https:// doi.org / 10.2147 / OTT.S95 600 DOI: 10.2147/OTT.S95600
Hochreiter M., Kohler T., Schweiger A. et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical Care, 2009;13 (3): R83 10.1186 / cc7903. DOI: 10.1186/cc7903
Brunkhorst F. M., Forycki Z. F., Wagner J. Identification of immunoactivation of infectious origin by procalcitonin in body fluids [Abstract]. In: First International Symposium in Iena of Intensive Care Medicine, 1996. Clin. Intensive Care Suppl. 7 / 1.
Leon A., Lepouse C., Cousson J., et al. Procalcitonin in pleural effusion as a marker of septic response. [Abstract]. In: Fifth Vienna Shock Forum, 1995
GBD 2015 LRI Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis 2017; published online Aug http://dx.doi.org / 10.1016 / S1473 - 3099 (17) 30 396-1
DOI: 10.1016/S1473-3099(17)30396-1
Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for adults in ambulatory care in the USA, 2007- 09. J Antimicrob Chemother 2014; 69: 234- 40. 10.1093 / jac / dkt301
DOI: 10.1093/jac/dkt301
Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among US adults. N Engl J Med 2015; 373: 415-27. 10.1056 / NEJMoa1 500 245
DOI: 10.1056/NEJMoa1500245
Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, Huber P, Muller B, Tamm M. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin- guidance with standard therapy. Chest. 2007 Jan;131 (1):9 -19. 10.1378 / Chest.06-1500
DOI: 10.1378/chest.06-1500
Schuetz P, Muller B, Christ- Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012;9: CD007 498. 10.1002 / 14 651 858. CD007 498.pub3
DOI: 10.1002/14651858.CD007498.pub3
Garnacho-Montero J, Gutierrez-Pizarraya A, Escoresca-Ortega A, et al. Deescalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014; 40:32- 40. 10.1007 / s00 134-013-3077-7
DOI: 10.1007/s00134-013-3077-7
Schuetz P, Balk R, Briel M, et al. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med 2015; 53:583-592. 10.1515 / cclm-2014-1015
DOI: 10.1515/cclm-2014-1015
Stojanovic I, Schneider JE, Wei L, et al. Economic evaluation of procalcitoninguided antibiotic therapy in acute respiratory infections: a Chinese hospital system perspective. Clin Chem Lab Med 2017; 55:561-570. 10.1515 / cclm-2016- 0349
DOI: 10.1515/cclm-2016-0349
Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2017; 10: CD 007 498. 10.1002 / 14 651 858. CD007 498.pub3
DOI: 10.1002/14651858.CD007498.pub3
Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level metaanalysis. Lancet Infect Dis 2018; 18:95-107. 10.1016 / S1473-3099 (17) 30 592-3.
DOI: 10.1016/S1473-3099(17)30592-3
Branche Angela, Neeser Olivia, Mueller Beat, Schuetz Philipp. Procalcitonin to guide antibiotic decision making. RESPIRATORY INFECTIONS: Edited by Michael S. Niederman: Curr Opin Infect Dis 2019; 32:130-135. 10.1097 / QCO.0 000 000 000 000 522
DOI: 10.1097/QCO.0000000000000522
Schuetz P, Kutz A, Grolimund E, et al. Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. Int J Cardiol 2014; 175:464- 472. 10.1016 / j.ijcard.2014.06.022.
DOI: 10.1016/j.ijcard.2014.06.022
Schuetz P, Daniels LB, Kulkarni P, et al. Procalcitonin: a new biomarker for the cardiologist. Int J Cardiol 2016; 223:390 -397. 10.1016 / j.ijcard.2016.08.204
DOI: 10.1016/j.ijcard.2016.08.204
Llewelyn MJ, Fitzpatrick JM, Darwin E, et al. The antibiotic course has had its day. BMJ 2017; 358: j3418. 10.1136 / BMJ.j3418
DOI: 10.1136/bmj.j3418
Schuetz P, Mueller B. Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes. Intensive Care Med 2014;40:141. 10.1007 / s00 134-013-3139-x.
DOI: 10.1007/s00134-013-3139-x
Carr JA. Procalcitonin-guided antibiotic therapy for septic patients in the surgical intensive care unit. Journal of Intensive Care, 2015; 3: 36. 10.1186 / s40 560-015-0100-9.
DOI: 10.1186/s40560-015-0100-9
Schuetz P., Chiappa V., Briel et al. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Archives of Internal Medicine, 2011; 171 (15): 1322-1331. 10. 1001 / archinternmed.2011.318
DOI: 10.1001/archinternmed.2011.318
Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008; 177:498-505. 10.1164 / rccm.200 708-1238OC
DOI: 10.1164/rccm.200708-1238OC
Schuetz P, Birkhahn R, Sherwin R, et al. Serial procalcitonin predicts mortality in severe sepsis patients: results from the multicenter procalcitonin Monitoring SEpsis (MOSES) study. Crit Care Med 2017; 45:781-789. 10.1097 / CCM.0 000 000 000 002 321
DOI: 10.1097/CCM.0000000000002321
van der Does Y, Limper M, Jie KE, et al. Procalcitonin-guided antibiotic therapy in patients with fever in a general emergency department population: a multicentre noninferiority randomized clinical trial (HiTEMP study). Clin Microbiol Infect 2018; 24:1282- 1289. 10.1016 / j.cmi.2018.05.011.
DOI: 10.1016/j.cmi.2018.05.011
Schuetz P, Falsey AR. Procalcitonin in patients with fever: one approach does not fit all. Clin Microbiol Infect 2018; 24:1229-1230. 10.1016 / j.cmi.2018.07.022
DOI: 10.1016/j.cmi.2018.07.022
Huang DT, Yealy DM, Filbin MR, Brown AM, Chang CH, Y, et al. Procalcitonin- guided use of antibiotics for lower respiratory tract infection. N Engl J Med 2018; 379:236-249. 10.1056 / NEJMoa1 802 670
DOI: 10.1056/NEJMoa1802670
Reynolds SC, Shorr AF, Muscedere J, J iang X, Heyland DK. Longitudinal changes in procalcitonin in a heterogeneous group of critically ill patients. Crit Care Med 2012; 40: 2781- 87. 10.1097 / CCM.0b013e31 825b89cc
DOI: 10.1097/CCM.0b013e31825b89cc
Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 2014; 42: 1749-55. 10.1097 / CCM.0 000 000 000 000 330
DOI: 10.1097/CCM.0000000000000330
Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010; 38: 1045-53. 10.1097 / CCM.0b013e3181cc4824
DOI: 10.1097/CCM.0b013e3181cc4824
Fontela PS, Quach C, Karim ME, et al. Determinants of antibiotic tailoring in pediatric intensive care: a national survey. Pediatr Crit Care Med 2017; 18: e395 - e405. 10.1097 / PCC.0 000 000 0 00 001 238
DOI: 10.1097/PCC.0000000000001238
Cremieux AC, Muller-Serieys C, Panhard X, et al. Emergence of resistance in normal human aerobic commensal flora during telithromycin and amoxicillin- clavulanic acid treatments. Antimicrob Agents Chemother 2003; 47: 2030 - 35. 10.1128 / AAC.47.6.2030 -2035.2003
DOI: 10.1128/AAC.47.6.2030-2035.2003
van Bijnen EME, Paget J, de Lange-de Klerk ESM, et al. Antibiotic exposure and other risk factors for antimicrobial resistance in nasal commensal Staphylococcus aureus: an ecological study in 8 European countries. PLoS One 2015; 10: e0 135 094. doi.org / 10.1371 / journal.pone.0 135 094
DOI: 10.1371/journal.pone.0135094
Dubos F., Korczowski B., Aygun D.A. et al. Distinguishing between bacterial and aseptic meningitis in children: European comparison of two clinical decision rules. Arch. Dis. Child., 2010; 95: 963-967. 10.1136 / adc.2010.186 056
DOI: 10.1136/adc.2010.186056
Leroy S., Gervaix A. Procalcitonin: a key marker in children with urinary tract infection. Adv. Urol., 2011;397 618 21 274 426. 10.1155 / 2011 / 397 618
DOI: 10.1155/2011/397618
Galetto-Lacour A., Alcoba G., Posfay-Barbe K.M. et al. Elevated inflammatory markers combined with positive pneumococcal urinary antigen are a good predictor of pneumococcal community- acquired pneumonia in children. Pediatr. Infect. Dis J., 2013; 32 (11): 1175-1179. 10.1097 / INF.0b013e31 829ba62a
DOI: 10.1097/INF.0b013e31829ba62a
Westwood ME, Ramaekers BLT, Whiting P, Tomini F, Joore MA, Armstrong N, et al. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health Technol Assess 2015;19 (96). 10.3310 / hta19 960
DOI: 10.3310/hta19960
Mewes JC, Pulia MS, Mansour MK, Broyles MR, Nguyen HB, Steuten LM (2019) The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: A health economic model analysis. PLoS ONE 14 (4): e0 214 222. https:// doi.org / 10.1371 / journal.pone.0 214 222
DOI: 10.1371/journal.pone.0214222
Iankova I, Thompson-Leduc P, Kirson NY, Rice B, Hey J, Krause A, et al. Efficacy and safety of procalcitonin guidance in patients with suspected or confirmed sepsis: a systematic review and meta- analysis. Crit Care Med. 2018;46:691- 698. 10.1097 / CCM. 0 000 000 000 002 928.
DOI: 10.1097/CCM.0000000000002928
Pa to u t M, Salaun M, Brunel V, Bota S, Ca u l i e z B, Thiberville L. Diagnostic and prognostic value of serum procalcitonin concentrations in primary lung cancers. Clin Biochem. 2014;47 (18):263-267. 10.1016 / j.clinbiochem.2014.09.002
DOI: 10.1016/j.clinbiochem.2014.09.002
Schuttrumpf S, Binder L, Hagemann T, Berkovic D, Trumper L, Binder C. Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations. Clin Infect Dis. 2006;43 (4):468 - 473. 10.1086 / 505 394
DOI: 10.1086/505394
Schuetz P.B., Mueller, A. Trampuz. Contamination from Bloodstream Infection due to Coagulase-Negative Staphylococci. Infection, 2007, 35 (5): 352-355. 10.1007 / s15 010-007-7065-0
DOI: 10.1007/s15010-007-7065-0
Müller F, Christ- Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: A prospective cohort trial. Chest, 2010, 138: 121-129. 10.1378 / Chest.09-2920
DOI: 10.1378/chest.09-2920
Hanine El Haddad, Anne-Marie Chaftari, Ray Hachem, Patrick Chaftari, and Issam I. Raad. Biomarkers of Sepsis and Bloodstream Infections: The Role of Procalcitonin and Proadrenomedullin With Emphasis in Patients With Cancer. Clinical Infectious Diseases® 2018;67 (6):971-7. 10.1093 / cid / ciy331
DOI: 10.1093/cid/ciy331
Matzaraki V, Alexandraki KI, Venetsanou K, et al. Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis. Clin Biochem 2007;40:336- 42. 10.1016 / j. clinbiochem.2006.10.027
DOI: 10.1016/j.clinbiochem.2006.10.027
Chaftari AM, Hachem R, Reitzel R, et al. Role of procalcitonin and interleukin-6 in predicting cancer, and its progression independent of infection. PLOS One 2015; 10: e0 130 999. 10.1371 / journal. pone.0 130 999
DOI: 10.1371/journal.pone.0130999
Ilhan N, Ilhan N, Ilhan Y, Akbulut H, Kucuksu M. C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer. World J Gastroenterol 2004; 10:1115- 20. 10.3748 / wjg.v10.i8.1115
DOI: 10.3748/wjg.v10.i8.1115
Ittner L, Born W, Rau B, Steinbach G, Fischer JA. Circulating procalcitonin and cleavage products in septicaemia compared with medullary thyroid carcinoma. Eur J Endocrinol 2002; 147:727-31. 10.1530 / eje.0.1 470 727
DOI: 10.1530/eje.0.1470727
Avrillon V, Locatelli-Sanchez M, Folliet L, et al. Lung cancer may increase serum procalcitonin level. Infect Disord Drug Targets 2015; 15:57- 63.
Shen H, Zheng S, Chen R, et al. Prognostic significance of serum procalcitonin in patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization: a retrospective analysis of 509 cases. Medicine (Baltimore) 2017; 96: e7438. 10.1097 / MD.0 000 000 000 007 438
DOI: 10.1097/MD.0000000000007438
Chen L, Zhang Y, Lin Y, et al. The role of elevated serum procalcitonin in neuroendocrine neoplasms of digestive system. Clin Biochem 2017; 50:982-7. 10.1016 / j.clinbiochem.2017.06.010
DOI: 10.1016/j.clinbiochem.2017.06.010
Yaegashi H, Izumi K, Kitagawa Y, et al. Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer: the role of procalcitonin. Int J Urol 2014; 21:104- 6. 10.1111 / iju.12 178.
DOI: 10.1111/iju.12178
Shomali W, Hachem R, Chaftari AM, et al. Can procalcitonin distinguish infectious fever from tumor-related fever in non- neutropenic cancer patients? cancer 2012; 118: 5823 - 9. 10.1002 / cncr.27 602.
DOI: 10.1002/cncr.27602
Gac AC, Parienti JJ, Chantepie S, et al. Dynamics of procalcitonin and bacteremia in neutropenic adults with acute myeloid leukemia. Leuk Res. 2011;35 (10):1294 -1296. 10.1016 / j. leukres.2011
DOI: 10.1016/j.leukres.2011
Carnino L, Betteto S, Loiacono M, et al. Procalcitonin as a predictive marker of infections in chemoinduced neutropenia. J Cancer Res Clin Oncol. 2010;136 (4):611- 615. 10.1007 / s00 432-009-0699-9
DOI: 10.1007/s00432-009-0699-9
Al Shuaibi M, Bahu RR, Chaftari AM, et al. Pro-adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in febrile patients with hematologic malignancies. Clin Infect Dis 2013; 56:943-50. 10.1093 / cid / cis1029
DOI: 10.1093/cid/cis1029
Lucena CM, Rovira M, Gabarrus A, et al. The clinical value of biomarkers in respiratory complications in hematopoietic SCT. Bone Marrow Transplant 2017;52:415-22. 10.1038 / bmt.2016.280
DOI: 10.1038/bmt.2016.280
Debiane L, Hachem RY, Al Wohoush I, et al. The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer*. Crit Care Med 2014; 42:2500-7. 10.1097 / CCM.0 000 000 000 000 526
DOI: 10.1097/CCM.0000000000000526
Rast AC, Kutz A, Felder S, et al. Procalcitonin improves the Glasgow Prognostic Score for outcome prediction in emergency patients with cancer: a cohort study. Dis Markers 2015; 2015:795 801. 10.1155 / 2015 / 795 801
DOI: 10.1155/2015/795801
Ahn S, Lee YS, Lim KS, Lee JL. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Support Care Cancer 2013; 21:2303- 8. 10.1007 / s00 520-013-1787-6
DOI: 10.1007/s00520-013-1787-6
Lima SS, Nobre V, de Castro Romanelli RM, et al. Procalcitonin- guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Ann Hematol 2016; 95:1169-76. 10.1007 / s00 277-016-2639-5
DOI: 10.1007/s00277-016-2639-5
Haddad HE, Chaftari AM, Hachem R, et al. Procalcitonin guiding antimicrobial therapy duration in febrile cancer patients with documented infection or neutropenia. Sci Rep 2018; 8:1099. 10.1038 / s41 598-018-19 616-3
DOI: 10.1038/s41598-018-19616-3
Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, BeaucheminM, Carlesse F, Groll AH, Haeusler GM, Santolaya M, Steinbach WJ, Castagnola E, Davis BL, Dupuis LL, Gaur AH, Tissing WJE, Zaoutis T, Phillips R, Sung L. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol 2017; 35:2082-2094. 10.1200 / JCO.2016.71.7017
DOI: 10.1200/JCO.2016.71.7017
Miedema KGE, De Bont ESJM, Elferink RFMO et al. The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer. 2011; 19:1593-1600. https://doi.org / 10.10 07 / s00 520-010-0987-6
DOI: 10.1007/s00520-010-0987-6
Hodgson-Viden H, Grundy PE, Robinson J L et al. Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia. BMC Pediatr. 2005; 5:10. https://doi.org / 10.1186 / 1471-2431-5-10
DOI: 10.1186/1471-2431-5-10
Hilde T. van der Galiën & Erik A.H. Loeffen & Karin G.E. Miedema1 & Wim J.E. Tissing. Predictive value of PCT and IL-6 for bacterial infection in children with cancer and febrile neutropenia. Supportive Care in Cancer. 2018; 26:3819-3826. https://doi.or g / 10.1007 / s00 520-018-4249-3
DOI: 10.1007/s00520-018-4249-3

Еще

Статья научная